Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis o

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis o
Type de publicationJournal Article
Year of Publication2021
AuteursVan Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argiles G, Borg C, Glynne-Jones R, Punt CJA, van de Wouw AJ, Fedyanin M, Stroyakovskiy D, Kroening H, Garcia-Alfonso P, Wasan HSingh, Falcone A, Aubel P, Egorov A, Amellal N, Moiseenko V
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume39
Date PublishedJAN 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2021.39.3_suppl.14